Sequent Medical, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sequent Medical, Inc.
US FDA's Neurological Device Panel is set to meet Sept. 27 to weigh the merits of a PMA submitted for the WEB embolization device for treating aneurysms.
Not all of the key medtech deals of 2016 were blockbusters. Herein are some of the more interesting smaller deals of the year.
Celgene and Novartis each signed $3 billion immuno-oncology deals, with Jounce and Xencor, respectively; Galenica Group made a $1.5 billion acquisition for a hyperkalaemia drug. Public financings grew from May to July in the biopharma industry, but decreased month over month in the device sector.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2016.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.